Australian Longevity Institute

The Australian Longevity Institute (ALI) is a biotechnology and clinical research company dedicated to the development and validation of longevity-enhancing interventions. Based in Queensland and collaborating with Griffith University, the institute focuses on the pharmacological optimization of geroscience-based therapeutics, particularly the mTOR inhibitor rapamycin (sirolimus). ALI is currently conducting clinical trials to evaluate the bioavailability of various rapamycin formulations, including sublingual delivery systems, to establish safe and effective protocols for healthspan extension. The company serves as a bridge between academic research and clinical application in the emerging field of longevity medicine.